WOCKPHARMA price chart
Daily close · 5-year history
Instrument details
Identifiers & classification
- Symbol
- WOCKPHARMA
- MB Code
- MBEQU5347
- ISIN
- INE049B01025
- BSE code
- 532300
- Industry group
- Pharmaceuticals & Biotechnology
- Screener
- View peers →
Latest earnings
Most recent declared quarter
- Quarter
- Mar 2026
- Revenue
- 965 Cr
- Net profit
- 164 Cr
- EPS
- 10.22
- YoY revenue
- +29.88%
Company documents
11 PDFs across 4 categories
Audited annual reports & financial statements
Earnings call transcripts & Q&A
Investor decks & strategy updates
Exchange filings & corporate announcements
Corporate timeline
Earnings, news & corporate actions for WOCKPHARMA
Wockhardt shares rose after USFDA approved Zaynich (WCK 5222), a novel antibiotic for complicated UTIs, making it India’s first indigenou…
Wockhardt shares jumped up to 16% after the US FDA cleared its novel antibiotic Zaynich, a key regulatory milestone that could boost the …
Wockhardt jumped 19% after USFDA approved Zaynich (cefepime and zidebactam), a novel IV antibiotic for serious infections, fueling a 75% …
Wockhardt rose 11.55% to Rs 2,266.10 after the U.S. FDA approved its novel antibiotic ZAYNICH, a regulatory win that could support future…
Wockhardt said its Zaynich antibiotic could peak at $1.5 billion in sales, with a US launch targeted by year-end and an India launch plan…
Wockhardt gained focus after USFDA approved Zaynich, its IV antibiotic for complicated UTIs in adults; the drug had earlier received QIDP…
Wockhardt rose over 9% after CDSCO approved import and marketing of Zaynich in India for adult cUTI, including pyelonephritis and Gram-ne…
Wockhardt said CDSCO has approved import and marketing of Zaynich (zidebactam/cefepime) in India for adults with complicated UTI, backed …
Price returns
Historical performance
Technicals
Indicator consensus